FibroGen
Javier Moreno possesses extensive experience in clinical trial management and research, having held positions such as Senior Clinical Trial Manager at FibroGen, Inc. and Clinical Trial Manager at both Neurocrine Biosciences and Tocagen Inc. Additionally, Javier served as a Senior Clinical Research Associate and progressed through the roles of Clinical Research Associate II and Clinical Research Associate I at Conatus Pharmaceuticals Inc. Educationally, Javier holds a Bachelor of Science degree in Molecular Biology from UC San Diego.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.